Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial

• Published in: Epilepsia (Copenhagen) Vol. 62; no. 9; pp. 2228 - 2239
• Main Authors: Patel, Anup D., Mazurkiewicz‐Bełdzińska, Maria, Chin, Richard F., Gil‐Nagel, Antonio, Gunning, Boudewijn, Halford, Jonathan J., Mitchell, Wendy, Scott Perry, Michael, Thiele, Elizabeth A., Weinstock, Arie, Dunayevich, Eduardo, Checketts, Daniel, Devinsky, Orrin
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2021
• Subjects: Adverse events; Anticonvulsants - adverse effects; Cannabidiol; Cannabidiol - therapeutic use; cannabinoid; Cannabinoids; childhood onset epilepsy; Clinical trials; Convulsions & seizures; Diarrhea; drop seizures; Encephalopathy; Epilepsies, Myoclonic - drug therapy; Epilepsy; epileptic encephalopathy; Fever; Humans; Lennox Gastaut Syndrome - drug therapy; Patients; Safety; Seizures; Seizures - drug therapy; Transaminase; treatment resistant; Valproic acid; childhood onset epilepsy; treatment resistant; drop seizures; cannabinoid; epileptic encephalopathy

Summary Objective Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add‐on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two randomized controlled trials (RCTs). Patients who completed the RCTs were in...